Abcellera Biologics Stock Market Value
| ABCL Stock | USD 3.13 0.04 1.26% |
| Symbol | Abcellera |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Abcellera Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.459 | Earnings Share (0.57) | Revenue Per Share | Quarterly Revenue Growth 0.376 | Return On Assets |
Understanding Abcellera Biologics requires distinguishing between market price and book value, where the latter reflects Abcellera's accounting equity. The concept of intrinsic value - what Abcellera Biologics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Abcellera Biologics' price substantially above or below its fundamental value.
Understanding that Abcellera Biologics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Abcellera Biologics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Abcellera Biologics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Abcellera Biologics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Abcellera Biologics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Abcellera Biologics.
| 11/21/2025 |
| 02/19/2026 |
If you would invest 0.00 in Abcellera Biologics on November 21, 2025 and sell it all today you would earn a total of 0.00 from holding Abcellera Biologics or generate 0.0% return on investment in Abcellera Biologics over 90 days. Abcellera Biologics is related to or competes with Celldex Therapeutics, Vera Therapeutics, Janux Therapeutics, Spyre Therapeutics, Biohaven Pharmaceutical, Sionna Therapeutics, and Immunome. AbCellera Biologics Inc. develops antibody discovery platform More
Abcellera Biologics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Abcellera Biologics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Abcellera Biologics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 28.69 | |||
| Value At Risk | (7.10) | |||
| Potential Upside | 6.33 |
Abcellera Biologics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Abcellera Biologics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Abcellera Biologics' standard deviation. In reality, there are many statistical measures that can use Abcellera Biologics historical prices to predict the future Abcellera Biologics' volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.38) | |||
| Total Risk Alpha | (0.48) | |||
| Treynor Ratio | (0.08) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Abcellera Biologics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Abcellera Biologics February 19, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.07) | |||
| Mean Deviation | 3.32 | |||
| Coefficient Of Variation | (1,853) | |||
| Standard Deviation | 4.67 | |||
| Variance | 21.81 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.38) | |||
| Total Risk Alpha | (0.48) | |||
| Treynor Ratio | (0.08) | |||
| Maximum Drawdown | 28.69 | |||
| Value At Risk | (7.10) | |||
| Potential Upside | 6.33 | |||
| Skewness | 0.2081 | |||
| Kurtosis | 2.33 |
Abcellera Biologics Backtested Returns
Abcellera Biologics secures Sharpe Ratio (or Efficiency) of -0.018, which signifies that the company had a -0.018 % return per unit of standard deviation over the last 3 months. Abcellera Biologics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Abcellera Biologics' risk adjusted performance of (0.03), and Mean Deviation of 3.32 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 3.12, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Abcellera Biologics will likely underperform. At this point, Abcellera Biologics has a negative expected return of -0.0848%. Please make sure to confirm Abcellera Biologics' value at risk, rate of daily change, and the relationship between the total risk alpha and kurtosis , to decide if Abcellera Biologics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.29 |
Poor predictability
Abcellera Biologics has poor predictability. Overlapping area represents the amount of predictability between Abcellera Biologics time series from 21st of November 2025 to 5th of January 2026 and 5th of January 2026 to 19th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Abcellera Biologics price movement. The serial correlation of 0.29 indicates that nearly 29.0% of current Abcellera Biologics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.29 | |
| Spearman Rank Test | 0.46 | |
| Residual Average | 0.0 | |
| Price Variance | 0.26 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Abcellera Biologics Correlation, Abcellera Biologics Volatility and Abcellera Biologics Performance module to complement your research on Abcellera Biologics. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Abcellera Biologics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.